Trial Profile
A Phase 1, Single and Multiple-Dose, Open-Label Study in Healthy Subjects to Assess the Effect of the Acid Reducing Agents, Omeprazole (OME) and Famotidine (FAM), on the Pharmacokinetics (PK) of Cenicriviroc Mesylate (CVC)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Nov 2017
Price :
$35
*
At a glance
- Drugs Cenicriviroc (Primary) ; Famotidine; Omeprazole
- Indications Cancer; Diabetic neuropathies; Graft-versus-host disease; HIV-1 infections; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Primary sclerosing cholangitis
- Focus Pharmacokinetics
- Sponsors Tobira Therapeutics
- 21 Nov 2017 Status changed from active, no longer recruiting to completed.
- 18 Apr 2016 Status changed from recruiting to active, no longer recruiting.
- 20 Feb 2016 New trial record